戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 f 11 patients [45.5%] diagnosed with actinic keratoses).
2 h approximately 30% having 5 or more actinic keratoses.
3 gines or seborrheic keratoses, and 3 actinic keratoses.
4  reduce the rate of new premalignant actinic keratoses.
5 s in human skin SCC and precancerous actinic keratoses.
6 heir premalignant precursor lesions, actinic keratoses.
7  is effective for field treatment of actinic keratoses.
8 n eradicate clinical and subclinical actinic keratoses.
9  melanocytic nevi, blue nevi, and seborrheic keratoses.
10 ell as dysplastic precursor lesions, actinic keratoses.
11 ormalities, pigment dyschromias, and actinic keratoses.
12 ple of 40 skin lesions (8 nevi, 8 seborrheic keratoses, 7 basal cell carcinomas, 7 melanomas, 4 heman
13                                      Actinic keratoses, a precancerous benign skin growth and precurs
14 es, such as actinic keratoses and seborrheic keratoses, achieving 92% sensitivity and specificity.
15                                      Actinic keratoses (AK) are common premalignant skin lesions with
16                         Precancerous actinic keratoses (AKs) (17) and SCCs (27) expressed two telomer
17 for identifying transformation-prone actinic keratoses (AKs) and aggressive squamous cell carcinoma (
18 n skin and subsequent development of actinic keratoses (AKs) and skin cancers.
19                                      Actinic keratoses (AKs) are lesions of epidermal keratinocyte dy
20 factors, and longitudinal outlook of actinic keratoses (AKs) are limited.
21                                      Actinic keratoses (AKs) are small scaly red areas of skin charac
22  effective in reducing the number of actinic keratoses (AKs) for up to 6 months, but no randomized tr
23                      The presence of actinic keratoses (AKs) increases a patient's risk of developing
24 thyl 5-aminolevulinic acid (MAL) for actinic keratoses (AKs) is as effective as conventional photodyn
25 lly favorable treatment modality for actinic keratoses (AKs).
26 y (PDT) is used extensively to treat actinic keratoses(AKs).
27 -cell and basal-cell carcinomas) and actinic keratoses among high-risk immunocompetent patients.
28             At 3-monthly visits, new actinic keratoses and basal-cell carcinomas were identified and
29 ations are seen in later precancers (actinic keratoses and Bowen's disease).
30  intraepithelial carcinoma including actinic keratoses and Bowen's disease; basal cell carcinoma; ben
31                                      Actinic keratoses and cutaneous squamous cell carcinomas are ass
32  and C1s was lower in cSCCs in situ, actinic keratoses and in normal skin.
33 oamputation, distinctive starfish-like acral keratoses and moderate degrees of deafness.
34 f promoting sunscreen use to prevent actinic keratoses and nonmelanoma skin cancer.
35 ancerous skin abnormalities, such as actinic keratoses and seborrheic keratoses, achieving 92% sensit
36  mutant p53 clusters associated with actinic keratoses and squamous cell carcinomas.
37 in cancer biopsies for the presence of solar keratoses and the extent of solar elastosis.
38                             Treating actinic keratoses and the surrounding skin area (i.e., field the
39 D4+ T cell-mediated immunity against actinic keratoses and, potentially, cancers of the skin and othe
40 carcinomas, 7 solar lentigines or seborrheic keratoses, and 3 actinic keratoses.
41 lti-omic profiling of keratinocytes, actinic keratoses, and cSCCs.
42  cSCC in situ, actinic keratoses, seborrheic keratoses, and normal skin.
43  five squamous cell carcinomas, five actinic keratoses, and one case of Bowen's disease) and HaCaT an
44 uding in normal skin, warts, dysplastic PUVA keratoses, and squamous cell carcinomas.
45 tinocyte carcinomas versus benign seborrheic keratoses; and malignant melanomas versus benign nevi.
46                        Surprisingly, actinic keratoses are often not related to their neighboring cSC
47                                      Actinic keratoses arose in 9% of grafts treated with ultraviolet
48 arcinomas, squamous cell carcinomas, actinic keratoses, atypical nevi, melanocytic nevi, blue nevi, a
49 ed peeling skin, leukonychia, acral punctate keratoses, cheilitis, and knuckle pads, which we propose
50  in the 5 years prior to enrollment, actinic keratoses count at enrollment, a history of ever use of
51 ciformis keratosis and in some cases actinic keratoses demonstrated similar histology associated with
52 al-cell carcinomas and the number of actinic keratoses during the 12-month intervention period, the n
53  methods are viable ways to evaluate actinic keratoses, even when the investigators differ at differe
54  cancer, seven of 17 (41.2%) dysplastic PUVA keratoses, four of five (80%) skin warts, and four of 12
55 nce of untreated skin malignancy and actinic keratoses in high-risk kidney and liver transplant recip
56  of new nonmelanoma skin cancers and actinic keratoses in high-risk patients.
57 r numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant rec
58 6.3% mean reduction in the number of actinic keratoses in participants (P < 0.0001).
59 ikiloderma with Hair abnormalities and Acral Keratoses), in four affected individuals from two UK fam
60 = 11) than in cSCC in situ (n = 69), actinic keratoses (n = 63), and normal skin (n = 5).
61                                      Actinic keratoses on the face and ears were counted by study der
62 , we randomly assigned patients with actinic keratoses on the face or scalp or on the trunk or extrem
63 ssigned, in a 1:1 ratio, adults with actinic keratoses on the face or scalp to receive either topical
64 tive cells, unlike the situation for actinic keratoses or basal cell carcinomas.
65 entage of reduction in the number of actinic keratoses (primary outcome), local skin reactions, and i
66 for 2 or 3 consecutive days to treat actinic keratoses produced clinically relevant sustained clearan
67 ional profiling of cSCCs adjacent to actinic keratoses reveals TERT promoter and CDKN2A mutations eme
68 (ROC = 0.823); and melanomas from seborrheic keratoses (ROC = 0.898).
69 plaques, and large tumors resembling actinic keratoses, SCC in situ, and SCCs, respectively.
70 ed cSCCs compared with cSCC in situ, actinic keratoses, seborrheic keratoses, and normal skin.
71 those for presumptive skin cancer or actinic keratoses, skin biopsies, or PCP diagnostic accuracy wit
72                                   Seborrheic keratoses (SKs) are common benign skin tumors that share
73                                   Seborrheic keratoses (SKs) are common, benign epithelial tumors of
74  were included, and patients with seborrheic keratoses (SKs) were included as a comparator group.
75 ious skin cancer excisions, previous actinic keratoses, smoking status, and height) and 2 statistical
76 pproved for the topical treatment of actinic keratoses, superficial basal cell carcinoma, and genital
77  target genes were activated in some actinic keratoses, the major precancerous lesion in human skin.
78 sing option to evaluate emerging new actinic keratoses therapies.
79                 Dermatologists treat actinic keratoses to prevent non-melanoma skin cancer.
80 h intervention period, the number of actinic keratoses until 6 months after randomization, safety, an
81                        The number of actinic keratoses was 11% lower in the nicotinamide group than i
82           The annualised rate of new actinic keratoses was 8.2 among the patients assigned T4N5 lipos
83 inoma and basal cell carcinoma), and actinic keratoses was compared between vitiligo cases and contro
84 ve measures, other skin cancers, and actinic keratoses were not.
85 tly younger, had more nevi but fewer actinic keratoses, were more likely to report a family history o
86 moter and CDKN2A mutations emerge in actinic keratoses, whereas additional mutations that inactivate
87 with premalignant lesions resembling actinic keratoses, whereas those in the heterozygous and wild-ty